Neuro Rehabilitation News
-
BlueWind Medical Ltd. Makes Key Additions to Leadership Team
BlueWind Medical, in preparation for commercialization of the RENOVA product line, announces the hiring of key positions within the organization. Vice President of Sales Mike Ruger, Vice President of Marketing Sandra Muhlfeld, and Vice President of Human Resources Lisa Mead. BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment ...
-
Synchron Announces First Human U.S. Brain-Computer Interface Implant
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in the U.S. using an endovascular BCI approach, which does not require invasive open-brain surgery. The procedure was performed at Mount Sinai West in ...
-
Synchron Appoints Kurt Haggstrom as Chief Commercial Officer
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. “I am honored and excited to join the Synchron team and be part of ...
-
Team Gleason Partners with Synchron to Redefine Accessibility
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an ...
-
Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
-
Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode for Severe Paralysis
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like material inserted ...
-
Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode Advances into Patients in US Clinical Trials
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. The members of the advisory board are visionaries across the technology, neuroscience and medical device industry, which include Edward ...
-
STEPS Budapest Center for Robotic Rehabilitation to Install deXtreme 3.1 for Commercial Evaluation
BioXtreme is proud to announce that a new commercial evaluation agreement was signed with STEPS Budapest Center for Robotic Rehabilitation. The agreement includes a 6- months evaluation period for deXtreme, by the end of which STEPS commits to purchasing the device (pending evaluation criteria are met). BioXtreme has developed a ground-breaking robotic device for motor-learning, based on ...
-
Synchron announces first direct-thought tweet, “Hello World,”using an implantable brain computer interface
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. Mr. O’Keefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface. Mr. O’Keefe, a 62-year-old man with amyotrophic ...
-
Bluewind Medical Ltd. to participate in Piper Sandler’s Virtual Healthcare Conference
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and CEO of ...
-
Bluewind Medical Ltd. to participate in Piper Sandler’s Virtual Healthcare Conference
Bluewind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and ...
-
Bluewind Medical Ltd. Completes OASIS Study Patient Enrollment
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States. OASIS is a ...
-
Villa Beretta Rehabilitation Center - BioXtreme Post Marketing Evaluation Site
Villa Beretta Rehabilitation Center and BioXtreme are proud to announce that they have agreed to conduct a joint evaluation project in the hospital’s facility in Costa-Masnaga, Italy. BioXtreme has developed a ground-breaking robotic device for motor-learning, based on innovative error enhancement technology for upper limb rehabilitation from stroke and other neurological injuries. Villa ...
-
Synchron receives green light from FDA to begin breakthrough trial of implantable brain computer interface in US
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety ...
-
Neuspera Medical Completes First Implants of its Neuromodulation Device in its two-stage Pivotal Clinical Trial to treat Urinary Urgency Incontinence
Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors. ...
-
We are proud to announce that BioXtreme is awarded a R&D grant from the Israel Innovation Authority
We are proud to announce that BioXtreme was awarded a R&D grant from the Israel Innovation Authority (coupled with additional investment from our strategic investor) in the amount of $1M. The grant will be used to further develop and improve our groundbreaking solution, deXtreme, as well as develop a future finger grip product (either as a complementary product for deXtreme or an autonomous ...
-
BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors. Mr. Cohen, an accredited public company director, has nearly 40 years of experience leading and guiding a variety of private and publicly traded life ...
-
BlueWind Initiates U.S. Enrollment in Clinical Trial of the RENOVA iStim to Treat Overactive Bladder
BlueWind Medical announced today that enrollment has commenced at U. S. sites in the Pivotal Clinical Trial of the RENOVA iStim™ implantable tibial neuromodulation System (RENOVA) for the treatment of Overactive Bladder (OAB) following conditional Investigative Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). There are approximately 40 million adults in the ...
-
Orchestra BioMed Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced senior-level appointments to its product development teams. Juan Lorenzo, an expert in vascular devices, joins as vice president, product development, Focal Therapies and will ...
-
Bioelectronics startup Neuspera nets $26M in Two-Tranche Series B
Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants. Each of the round’s original investors returned to participate, including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, Delta ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you